deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT01935973

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

A Randomized Phase I Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer NCT #01935973

Sponsor: NRG Oncology

Conditions Endometrial Adenocarcinoma Endometrial Clear Cell Adenocarcinoma Endometrial Mixed Cell Adenocarcinoma Endometrial Serous Adenocarcinoma Endometrial Undifferentiated Carcinoma Recurrent Uterine Corpus Cancer
Interventions Laboratory Biomarker Analysis Trametinib Uprosertib
Updated 20 times since 2017 Last updated: Oct 13, 2020 Started: Sep 30, 2013 Primary completion: Sep 8, 2015 Completion: Sep 8, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Endometrial Adenocarcinoma and Endometrial Clear Cell Adenocarcinoma, this trial is completed. The trial is conducted by NRG Oncology and has accumulated 20 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Oct 2017 · 5 months · monthly snapshot~Oct 2017 – ~Feb 2018 · 4 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jan 2019 · 6 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Jul 2019 · 4 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Jan 2020 · 5 months · monthly snapshot~Jan 2020 – ~Jul 2020 · 6 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 15 earlier versions

  1. Oct 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1

  2. Aug 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1

  5. Aug 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1

  6. Jul 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1

  7. Mar 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE1

  8. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1

  9. Jul 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1

  10. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE1

  11. Feb 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  12. Oct 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE1

    Phase: PHASE2 → PHASE1

  13. May 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE2

  14. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE2

  15. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NRG Oncology
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Augusta, United States , Baltimore, United States , Charleston, United States , Charlotte, United States , Charlottesville, United States , Chicago, United States , Cleveland, United States , Columbus, United States , Hartford, United States and 10 more locations